Contineum Therapeutics, Inc. Class A (CTNM)
NASDAQ:CTNM
Top Page
Contineum Therapeutics, Inc. Class A
(NASDAQ:CTNM)
Select Model
Select Model
Rating:50Neutral
Price Target:
$12.50
▼(-2.57% Downside)
Action:ReiteratedDate:03/06/26
The score is held back primarily by weak financial performance (no recurring revenue, widening losses, and rising cash burn), partially offset by a stronger balance sheet and liquidity runway. Technical signals are mixed but not bearish, while valuation is difficult to anchor due to negative earnings and no dividend. Corporate updates support long-term execution potential but introduce dilution risk via the expanded ATM.
Positive Factors
Strong cash balance & multi-year runway
A reported $262.9M cash balance and improved equity position give Contineum several years of runway (through mid‑2029), enabling continued clinical investment without immediate refinancing. This durable funding cushion reduces near‑term liquidity risk and supports multi‑year R&D execution.
Negative Factors
No recurring revenue and widening losses
Contineum lacks recurring operating revenue (zero in 2024–2025) and swung from profit in 2023 to substantial losses (net loss -$60M in 2025; EBIT -$68.1M). This structural absence of revenue forces reliance on financing and increases sensitivity to clinical and regulatory outcomes over the multi‑year development cycle.
Read all positive and negative factors
Positive Factors
Negative Factors
Strong cash balance & multi-year runway
A reported $262.9M cash balance and improved equity position give Contineum several years of runway (through mid‑2029), enabling continued clinical investment without immediate refinancing. This durable funding cushion reduces near‑term liquidity risk and supports multi‑year R&D execution.
Read all positive factors
Contineum Therapeutics, Inc. Class A (CTNM) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$497.25M
Dividend YieldN/A
Average Volume (3M)170.88K
Price to Earnings (P/E)―
Beta (1Y)0.57
Revenue GrowthN/A
EPS Growth-100.71%
CountryUS
Employees41
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.49
Shares Outstanding32,673,534
10 Day Avg. Volume105,448
30 Day Avg. Volume170,880
Financial Highlights & Ratios
PEG Ratio11.51
Price to Book (P/B)1.21
Price to Sales (P/S)0.00
P/FCF Ratio-5.70
Enterprise Value/Market Cap0.83
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-1.68K
Enterprise Value/Ebitda-6.46
Forecast
1Y Price Target
$22.20Price Target Upside73.03% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
EPS Forecast (FY)-2.06
Revenue Forecast (FY)$2.83M
Contineum Therapeutics, Inc. Class A Business Overview & Revenue Model
Company Description
Contineum Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on discovering and developing novel oral small molecule therapies for neuroscience, inflammation, and immunology indications with high unmet need. Its lead asset is ...
How the Company Makes Money
null...
Contineum Therapeutics, Inc. Class A Financial Statement Overview
Summary
Income Statement
28
Negative
Balance Sheet
60
Neutral
Cash Flow
35
Negative
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 0.00 | 0.00 | 50.00M | 0.00 | 0.00 |
| Gross Profit | -323.00K | -258.00K | 50.00M | -329.00K | 0.00 |
| EBITDA | -68.06M | -42.00M | 23.57M | -23.54M | -28.34M |
| Net Income | -59.98M | -42.26M | 22.72M | -24.25M | -29.00M |
Balance Sheet | |||||
| Total Assets | 276.64M | 212.85M | 130.39M | 50.64M | 70.52M |
| Cash, Cash Equivalents and Short-Term Investments | 262.90M | 204.76M | 125.19M | 47.24M | 69.00M |
| Total Debt | 8.25M | 6.26M | 193.19M | 5.85M | 4.91M |
| Total Liabilities | 15.65M | 14.78M | 198.32M | 11.37M | 8.93M |
| Stockholders Equity | 260.99M | 198.07M | -67.94M | 39.27M | 61.59M |
Cash Flow | |||||
| Free Cash Flow | -55.54M | -33.36M | 18.93M | -20.24M | -26.43M |
| Operating Cash Flow | -55.31M | -32.84M | 19.35M | -20.12M | -26.27M |
| Investing Cash Flow | -3.71M | -69.74M | -65.57M | 22.30M | -64.97M |
| Financing Cash Flow | 112.69M | 109.00M | 56.18M | -1.24M | 79.84M |
Contineum Therapeutics, Inc. Class A Technical Analysis
Negative
12.83
Price Trends
14.14
Negative
12.77
Positive
10.78
Positive
Market Momentum
-0.25
Negative
44.93
Neutral
40.67
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CTNM, the sentiment is Negative. The current price of 12.83 is below the 20-day moving average (MA) of 13.07, below the 50-day MA of 14.14, and above the 200-day MA of 10.78, indicating a neutral trend. The MACD of -0.25 indicates Negative momentum. The RSI at 44.93 is Neutral, neither overbought nor oversold. The STOCH value of 40.67 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for CTNM.
Contineum Therapeutics, Inc. Class A Risk Analysis
Contineum Therapeutics, Inc. Class A disclosed 78 risk factors in its most recent earnings report. Contineum Therapeutics, Inc. Class A reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Contineum Therapeutics, Inc. Class A Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
61 Neutral | $1.82B | -12.77 | -67.52% | ― | -52.08% | -69.35% | |
52 Neutral | $365.94M | -5.17 | -43.33% | ― | ― | 9.32% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | $497.25M | -5.28 | -30.40% | ― | ― | -100.71% | |
49 Neutral | $646.87M | -9.36 | -57.29% | ― | ― | -22.82% | |
48 Neutral | $487.01M | -5.39 | -55.83% | ― | ― | -52.86% | |
41 Neutral | $27.77M | -1.75 | -135.79% | ― | -53.67% | 86.75% |
* Healthcare Sector Average
CTNM
Contineum Therapeutics, Inc. Class A
12.83
8.70
210.65%
TVRD
Tvardi Therapeutics
2.96
-11.63
-79.71%
CAPR
Capricor Therapeutics
31.61
22.73
255.97%
DRTS
Alpha Tau Medical Ltd
7.35
4.85
194.00%
IMRX
Immuneering
5.66
4.42
356.45%
ENGN
enGene Holdings
7.27
3.27
81.75%
Contineum Therapeutics, Inc. Class A Corporate Events
Business Operations and StrategyFinancial DisclosuresPrivate Placements and Financing
Contineum Therapeutics Expands ATM Facility, Highlights Pipeline Progress
Positive
Mar 5, 2026
Contineum Therapeutics amended its existing at-the-market equity program with Leerink Partners on March 5, 2026, raising the total capacity for Class A common stock issuance to $100 million, excluding amounts already sold, while committing not to ...
Business Operations and StrategyRegulatory Filings and Compliance
Contineum Therapeutics Adopts 2026 Employment Inducement Equity Plan
Positive
Jan 26, 2026
On January 23, 2026, Contineum Therapeutics, Inc.’s board approved a new 2026 Employment Inducement Equity Incentive Plan, modeled largely on its 2024 Equity Incentive Plan but limited to non-incentive stock options and awards granted only t...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.